[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bowel-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bowel-cancer":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,46,79,116],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100619169","use-of-a-novel-camera-to-check-the-bowel-after-polyp-or-tumour-removal-100619169",false,"NCT07341126","Use of a Novel Camera to Check the Bowel After Polyp or Tumour Removal","Surveillance Digital Rectoscopy After Local Excision of Rectal Tumours","R-ALERT","Inclusion Criteria:\n\nAll participants who are capable of giving informed consent. All participants aged 16 years or over. All patients must have had a rectal tumour\u002F polyp removed within easy reach of the rigid sigmoidoscope.\n\nAll participants must be resident in the United Kingdom.\n\nExclusion Criteria:\n\nUnable to give informed consent. Under the age of 16 years","ALL","16 Years",{"count":20,"type":21},30,"ESTIMATED","OBSERVATIONAL","1.1 Polyps or tumours in the lower part of the bowel (rectum) can be removed using instruments inserted through the bottom which avoids major surgery and the possibility of a stoma bag (colostomy). Afterwards, it is important to check the area with regular camera tests. If checks are delayed, re-growths could be serious and may be untreatable. COVID and other factors have led to long waiting lists for camera checks and in NHS Lothian around 20% of all camera checks are done more than 6 months late.\n\nThe investigators want to try a new camera and approach that would allow us to reduce waiting lists. Using a short camera called a 'rectoscope' to check the lower bowel has already been shown to be safe, comfortable and acceptable to patients with other conditions. In fact, patients are unlikely to feel or realise any difference between the rectoscope and standard camera tests.\n\nThe investigators want to show that this 'rectoscope' can be safely used in the outpatient clinic with an enema (suppository) instead of strong bowel medicine taken by mouth the day before. This would mean the camera checks happen on time and would reduce waiting lists for other important tests.\n\nThe investigators will include 30 patients across three stages of our study. In the first set of patients, the investigators will use the rectoscope alongside the usual endoscope in the endoscopy room using the usual oral bowel medicine. This stage will check the rectoscope is acceptable to the patient and the doctor. In the next 10 patients the investigators will use a suppository instead of oral bowel medicine still using both cameras. Finally, the investigators will use the rectoscope in the outpatient clinic with an suppository to show this is an easy, effective and acceptable way to deliver timely camera checks.",[25,26,27,28,29],"Bowel Cancer","Polyp Rectal","Rectal Cancer","Rectal Adenocarcinoma","Rectal Adenoma",[31,32],"LumenEye","Rectoscopy","NOT_YET_RECRUITING","2026-05-28",{"date":36,"type":37},"2026-05-29","ACTUAL",{"date":39,"type":21},"2026-07-01",{"date":41,"type":21},"2027-05-01",{"name":43,"class":44},"University of Edinburgh","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":78},"100600270","phase-2-safety-and-effectiveness-study-of-pre-operative-artesunate-in-stage-ii-iii-colorectal-cancer-100600270","NCT07095309","Safety and Effectiveness Study of Pre-operative Artesunate in Stage II\u002F III Colorectal Cancer","Phase II Randomised, Double Blind, Placebo Controlled Trial of Neoadjuvant Artesunate in Stage II\u002FIII Colorectal Cancer","NeoART-M","Inclusion Criteria:\n\n* Aged 18 or over\n* Histologically proven single primary site colorectal adenocarcinoma or high grade dysplasia plus unequivocal radiological evidence of invasive cancer\n* Stage II\u002FIII colorectal cancer planned for surgical resection and no clinical indication for neoadjuvant preoperative chemotherapy\u002Fchemoradiation therapy\n* WHO performance status 0,1 or 2\n* Adequate full blood count: White Cell Count (WCC) \\>3.0 x 109 \u002Fl; Platelets \\>100 x 109\u002Fl; Haemoglobin (Hb) \\>80g\u002FL\n* Adequate renal function : Glomerular Filtration Rate \\>30ml\u002Fmin by Cockcroft-Gault formula.\n* Adequate hepatobiliary function : Total bilirubin \\\u003C 3 x Upper limit norm\n* Female participants of childbearing potential must have a negative pregnancy test \\\u003C72 hours prior to initiating study intervention and agree to avoid pregnancy using adequate, medically approved contraceptive precautions for up to 6 weeks after the last dose of study treatment interventions.\n* Male participants with a partner of childbearing potential must agree to use adequate, medically approved contraceptive precautions during and for up to 6 weeks after the last dose of the study treatment intervention.\n* Patient able and willing to provide written, informed consent for the study.\n\nExclusion Criteria:\n\n* Contraindication to use of artesunate due to hypersensitivity\n* Pregnancy or lactation\n* Male or female participants unwilling to use an effective method of birth control (either hormonal in the form of the contraceptive pill or barrier method of birth control accompanied by the use of a proprietary spermicidal foam\u002Fgel or film) ; or agreement of true abstinence from time consent is signed until 6 weeks after the last dose of study treatment intervention (i.e. withdrawal, calendar, ovulation, symptothermal and post ovulation are not acceptable methods)\n* History of hearing or balance problems\n* History of immunosuppression\n* Patient weight \\\u003C 52 kg or \\> 110 kg\n* Other planned intervention, apart from standard of care\n* Any other malignant disease diagnosis within the preceding 2 years with the exception of non-melanomatous skin cancer and carcinoma in situ\n* Lactose intolerance","18 Years",{"count":56,"type":21},120,"INTERVENTIONAL",[59],"PHASE2","TThis study evaluates the safety and effectiveness of pre-operative artesunate, given orally once a day for 14 days prior to surgery, in patients with Stage II\u002FIII colorectal cancer.\n\nArtesunate is an established antimalarial drug with an excellent safety profile. It is well tolerated, affordable, and widely available. Several laboratory studies and one small pilot clinical study in patients with colorectal cancer have shown that artesunate can reduce the proliferation and growth of cancer cells.\n\nOne hundred patients diagnosed with Stage II\u002FIII operable colorectal cancer will be randomly allocated to receive oral artesunate 200 mg daily or a matching placebo for 14 days prior to surgery. Patients will then be followed closely for 5 years to determine whether pre-operative artesunate reduces the risk of cancer recurrence after surgery.",[62,25],"Stage II\u002FIII Colon Cancer",[64,65,66,67],"artesunate","colorectal","drug repurposing","antimalarial","2025-07-23",{"date":70,"type":37},"2025-07-31",{"date":72,"type":21},"2025-08-15",{"date":74,"type":21},"2033-07-31",{"name":76,"class":77},"Metanoic Health Ltd.","INDUSTRY",6,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":87,"sex":17,"minAge":88,"maxAge":89,"enrollmentInfo":90,"targetDuration":4,"studyType":57,"phases":92,"briefSummary":94,"conditions":95,"keywords":99,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":115},"100591496","equita---a-feasibility-trial-of-a-faith-placed-intervention-to-increase-screening-uptake-in-black-adults-100591496","NCT06981182","EQUITA - A Feasibility Trial of a Faith-placed Intervention to Increase Screening Uptake in Black Adults","EQUITy in Black Adult Health (EQUITA) - a Randomised Feasibility Trial of a Co-produced and Faith-placed Intervention to Increase Uptake of Breast, Cervical, Bowel, and AAA Screening in the North East of England, Leeds and Scotland","EQUITA","Inclusion Criteria:\n\n* Members of participating churches (North East of England, Leeds, Scotland)\n* Self-identify as Black,\n* Female aged 25-74,\n* Male aged 50-74,\n* Not up to date with all screening tests for which they are eligible, e.g., women who are up to date with one form of screening (e.g., breast) will be eligible for recruitment if they are not up to date with others (e.g., cervical or bowel).\n\nExclusion Criteria:\n\n* Not a member of participating churches (North East of England, Leeds, Scotland).\n* Individuals who do not self-identify as Black\n* Do not self-identity as Black\n* Females aged outside the range of 25-74\n* Males aged outside the range of 50-74.\n* Individuals who are up to date with all screening tests for which they are eligible.",true,"25 Years","74 Years",{"count":91,"type":21},300,[93],"NA","The goal of this randomised feasibility trial is to examine feasibility and acceptability of a co-produced and faith-placed intervention to increase uptake of breast, cervical, bowel, and abdominal aortic aneurysm (AAA) screening among Black communities in the North East of England, Leeds and Scotland, United Kingdom (UK).\n\nParticipants will be invited to attend a two-hour workshop at each of the three study sites and will be randomly assigned to either the intervention group or the control group.\n\nThis 24-month feasibility study will inform the development of a full-scale randomised-controlled trial co-produced for Black people that uses culturally appropriate messages that support screening for early diagnosis in this underserved group.",[96,25,97,98],"Breast Cancer","Cervical Cancer","Abdominal Aortic Aneurysm",[100,96,25,97,98,101,102,103,104,105],"Cancer screening","Faith-placed intervention","Black adults","Randomised Controlled Trial","Feasibility study","Faith-based","2025-05-12",{"date":108,"type":37},"2025-05-20",{"date":110,"type":21},"2025-09-01",{"date":112,"type":21},"2027-02-28",{"name":114,"class":44},"University of Sunderland",3,{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":4,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":123,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":125,"conditions":126,"keywords":4,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":45},"100536634","assessing-frailty-and-its-impacts-on-patients-facing-major-gi-surgery-100536634","NCT06267378","Assessing Frailty and Its Impacts on Patients Facing Major GI Surgery","Assessing Frailty and Its Impacts in Older Patients Facing Major Gastrointestinal Surgery","Inclusion Criteria:\n\n1. Male or female.\n2. Aged 70 years and over.\n3. Patients with a diagnosis of primary operable colorectal cancer where treatment includes a planned curative surgical procedure.\n4. About to undergo elective surgery for cancer.\n5. Mental capacity to consent.\n\nExclusion Criteria:\n\n1. Patients with unresectable cancer.\n2. Patients presenting as an emergency.\n3. Patients who are having chemotherapy or radiotherapy before their surgery.",{"count":124,"type":21},100,"The study team will look at 3 new tests that will make it easier to measure frailty in patients awaiting surgery for cancer and compare them against standard clinical measures of frailty in a pilot study. The expected outcome is that evidence will be collated in order to apply for a major grant to look at improving the care of frail patients with cancer in the future.",[25],"RECRUITING","2024-07-05",{"date":130,"type":37},"2024-07-08",{"date":132,"type":37},"2023-08-30",{"date":134,"type":21},"2029-12-01",{"name":136,"class":44},"Doncaster And Bassetlaw Hospitals NHS Foundation Trust"]